U.S., Nov. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07246590) titled 'Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)' on Nov. 17.
Brief Summary: This is a Phase 3, double-blind, randomized, vehicle-controlled study (Study number VP-CW-301; referred to as COVE-2 [Cantharidin and Occlusion in Verruca Epithelium]) to evaluate the efficacy and safety of YCANTH (VP-102) treatment in subjects with common warts.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Common Warts
Common Warts (Verruca Vulgaris)
Human Papilloma Virus (HPV)
Warts
Intervention:
COMBINATION_PRODUCT: VP-102
A single-use applicator and applied in sufficient quantity to cover the...